Literature DB >> 25562164

MicroRNA-212 inhibits osteosarcoma cells proliferation and invasion by down-regulation of Sox4.

Xiao-Ji Luo1, Da-Gang Tang, Tian-Le Gao, Yan-Liang Zhang, Miao Wang, Zheng-Xue Quan, Jin Chen.   

Abstract

BACKGROUND: Multiple MicroRNAs (miRNAs) have been identified in the development and progression of osteosarcoma. However, the expression and roles of miR-212 in osteosarcoma remain largely undefined.
METHODS: Real-time PCR assays were used to detect the expression of miR-212 in human osteosarcoma tissues. MiR-212 mimics were introduced into MG63 and U2OS cells. Bioinformatic prediction was used to identify the potential targets of miR-212. Protein expression analysis, luciferase assays and rescue assays were used to confirm the substrate of miR-212.
RESULTS: miR-212 was significantly down-regulated in human osteosarcoma tissues, compared with adjacent normal tissues. Introduction of miR-212 mimics into MG63 and U2OS cells inhibited cell proliferation and invasion. Besides, miR-212 overexpression could also inhibit tumor growth in the nude mice. Additionally, bioinformatic prediction suggested that the sex-determining region Y-box 4 (Sox4) is a target gene of miR-212. Sox4 inhibition phenocopied the roles of miR-212, while restored expression of Sox4 dampened miR-212-mediated suppression of tumor progression.
CONCLUSION: The miR-212/Sox4 interaction plays an important role of in the osteosarcoma progression.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25562164     DOI: 10.1159/000369661

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  27 in total

1.  Enhanced Wnt signaling by methylation-mediated loss of SFRP2 promotes osteosarcoma cell invasion.

Authors:  Qiang Xiao; Yu Yang; Xuepu Zhang; Qing An
Journal:  Tumour Biol       Date:  2015-12-01

2.  miR-107 promotes hepatocellular carcinoma cell proliferation by targeting Axin2.

Authors:  Jun-Jie Zhang; Chen-Yu Wang; Long Hua; Kun-Hou Yao; Jiang-Tao Chen; Jun-Hong Hu
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 3.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

4.  Over-expression of Sox4 and β-catenin is associated with a less favorable prognosis of osteosarcoma.

Authors:  Zheng-Qi Bao; Chang-Chun Zhang; Yu-Zhou Xiao; Jian-Sheng Zhou; Yi-Sheng Tao; Da-Min Chai
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-04-13

Review 5.  Review of microRNA in osteosarcoma and chondrosarcoma.

Authors:  Le Chang; Swati Shrestha; Greg LaChaud; Michelle A Scott; Aaron W James
Journal:  Med Oncol       Date:  2015-04-26       Impact factor: 3.064

6.  Shikonin inhibits invasiveness of osteosarcoma through MMP13 suppression.

Authors:  Biyong Deng; Bing Qiu
Journal:  Tumour Biol       Date:  2015-06-24

7.  MicroRNA-212 functions as an epigenetic-silenced tumor suppressor involving in tumor metastasis and invasion of gastric cancer through down-regulating PXN expression.

Authors:  Daojiang Li; Zhengrong Li; Jianbo Xiong; Binbin Gong; Guoyang Zhang; Chao Cao; Zhigang Jie; Yi Liu; Yi Cao; Yufeng Yan; Hong Xiong; Lingyu Qiu; Miantian Yang; Hongping Chen; Shuping Jiang; Xiongwen Yang; Heping Chen
Journal:  Am J Cancer Res       Date:  2015-09-15       Impact factor: 6.166

8.  MicroRNA-212 suppresses the proliferation and migration of osteosarcoma cells by targeting forkhead box protein A1.

Authors:  Jian Liu; Bohua Chen; Bin Yue; Junde Yang
Journal:  Exp Ther Med       Date:  2016-11-07       Impact factor: 2.447

9.  MicroRNA-23a enhances migration and invasion through PTEN in osteosarcoma.

Authors:  K Tian; R Di; L Wang
Journal:  Cancer Gene Ther       Date:  2015-07-10       Impact factor: 5.987

10.  MiR-211 inhibits cell proliferation and invasion of gastric cancer by down-regulating SOX4.

Authors:  Chen-Yu Wang; Long Hua; Juan Sun; Kun-Hou Yao; Jiang-Tao Chen; Jun-Jie Zhang; Jun-Hong Hu
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.